Introduction of therapeutic reference pricing in Slovenia and its economic consequences

Abstract

The Slovenian TRP system was established as an effective cost-containment measure. However, pitfalls arising from a country-specific TRP should be considered when introducing this policy.

Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study

“…Private (out-of pocket) prescriptions account for less than 5% of all outpatient prescriptions in Slovenia 28 . The Slovenian healthcare system and health claims data have been described in detail elsewhere [28][29][30][31] .…”

The effects of reference pricing on housing market: Evidence from Shenzhen China

“…Although there are more empirical studies investigating the effectiveness of RP for pharmaceutical markets (e.g., Brekke et al, 2015;Koskinen et al, 2015;Mardetko and Kos, 2018), only a few of them have proposed theoretical models to incorporate the effect of RP for the market. To analyze potential effects of RP regulation implemented in 1989 in Germany, Zweifel and Crivelli (1996) propose a duopoly model in which some physicians may choose to take the substitutions of a given medicine that is priced above the reference price.…”

Evaluación de impacto de la regulación de precios sobre la demanda de medicamentos

“…Las estrategias metodológicas empleadas han sido variadas, incluyen: revisión sistemática de la literatura (Acosta et al 2014), diferencias en diferencias (Ghislandi, Armeni, and Jommi 2013;Stargardt 2010;Armeni, Jommi, and Otto 2016), variable instrumental (Siminski 2011;Dalen, Strøm, and Haabeth 2006), propensity score matching (Siminski 2011), modelos logit (Herr and Suppliet 2017;Dalen, Strøm, and Haabeth 2006), modelos de efectos fijos (Cho et al 2015), análisis de series temporales interrumpidas (Marđetko and Kos 2018) (Fraeyman et al n.d.) ("The Impact of Pricing and Patent Expiration on the Demand for Pharmaceuticals: An Examination of the Use of Broad-Spectrum Antimicrobials" n.d.), modelos teóricos (Gonçalves and Rodrigues 2018;Tomofumi and Anegawa 2004;Ridley and Zhang 2017;Universidad EAFIT et al 2013) o incluso la aplicación de varios modelos (Siminski 2011;Dalen, Strøm, and Haabeth 2006).…”

“…Las fuentes de información empleadas incluyeron: otros estudios (Acosta et al 2014), información agregada de ventas y cantidades de ciertos medicamentos (Ghislandi, Armeni, and Jommi 2013;Tomofumi and Anegawa 2004;Universidad EAFIT et al 2013;Armeni, Jommi, and Otto 2016;Dalen, Strøm, and Haabeth 2006;Fraeyman et al n.d.), datos de consumo a nivel individual de ciertas prescripciones (Stargardt 2010;Siminski 2011;Herr and Suppliet 2017;Cho et al 2015) que incluyeron reclamaciones ambulatorias de medicamentos "claim data" (Marđetko and Kos 2018), y prescripciones a nivel ambulatorio y durante hospitalización ("The Impact of Pricing and Patent Expiration on the Demand for Pharmaceuticals: An Examination of the Use of Broad-Spectrum Antimicrobials" n.d.).…”

“…Se ha planteado que la reasignación de la demanda puede darse hacia alternativas terapéuticas con la misma indicación pero que no han sido sujetas a regulación de precios (Marđetko and Kos 2018;Stargardt 2010). Otros autores estudiaron como la competencia entre medicamentos genéricos y pioneros en el mercado noruego podría responder a los procesos regulatorios.…”